Cosyntropin testing does not predict response to glucocorticoids in community-acquired pneumonia in a randomized controlled trial
- PMID: 30485501
- DOI: 10.1111/cen.13907
Cosyntropin testing does not predict response to glucocorticoids in community-acquired pneumonia in a randomized controlled trial
Abstract
Objective: Glucocorticoids have been shown to improve outcome in community-acquired pneumonia (CAP). However, glucocorticoids have potential side-effects, and treatment response may vary. It is thus crucial to select patients with high likelihood to respond favourably. In critical illness, cosyntropin testing is recommended to identify patients in need for glucocorticoids. We investigated whether cosyntropin testing predicts treatment response to glucocorticoids in CAP.
Design: Predefined secondary analysis of a randomized controlled trial.
Patients: Hospitalized patients with CAP.
Measurements: We performed 1 µg cosyntropin tests in a randomized trial comparing prednisone 50 mg for 7 days to placebo. We investigated whether subgroups based on baseline and stimulated cortisol levels responded differently to glucocorticoids with regard to time to clinical stability (TTCS) and other outcomes by inclusion of interaction terms into statistical models.
Results: A total of 326 patients in the prednisone and 309 patients in the placebo group were evaluated. Neither basal cortisol nor a Δcortisol <250 nmol/L after stimulation nor the combination of basal cortisol and Δcortisol predicted treatment response as measured by TTCS (all P for interaction >0.05). Similarly, we found no effect modification with respect to mortality, rehospitalization, antibiotic treatment duration or CAP-related complications (all P for interaction >0.05). However, glucocorticoids had a stronger effect on shortening length of hospital stay in patients with a baseline cortisol of ≥938 nmol/L (P for interaction = 0.015).
Conclusions: Neither baseline nor stimulated cortisol after low-dose cosyntropin testing at a dose of 1 µg predicted glucocorticoid responsiveness in mild to moderate CAP. A treatment decision for or against adjunct glucocorticoids in CAP should not be made depending on cortisol values or cosyntropin testing results.
Trial registration: ClinicalTrials.gov NCT00973154.
Keywords: ACTH test; adrenal function; community-acquired pneumonia; cosyntropin test; critical illness-related corticosteroid insufficiency; glucocorticoids.
© 2018 John Wiley & Sons Ltd.
Comment in
-
Demystifying adrenal dysfunction in severe illness.Clin Endocrinol (Oxf). 2019 Sep;91(3):372-373. doi: 10.1111/cen.14054. Epub 2019 Jul 10. Clin Endocrinol (Oxf). 2019. PMID: 31292992 No abstract available.
Similar articles
-
Cytokines and Cortisol - predictors of treatment response to corticosteroids in community-acquired pneumonia?J Intern Med. 2019 Jul;286(1):75-87. doi: 10.1111/joim.12891. Epub 2019 Mar 14. J Intern Med. 2019. PMID: 30873676 Clinical Trial.
-
Benefit of adjunct corticosteroids for community-acquired pneumonia in diabetic patients.Diabetologia. 2016 Dec;59(12):2552-2560. doi: 10.1007/s00125-016-4091-4. Epub 2016 Sep 10. Diabetologia. 2016. PMID: 27614658 Clinical Trial.
-
Corticosteroid treatment for community-acquired pneumonia--the STEP trial: study protocol for a randomized controlled trial.Trials. 2014 Jun 28;15:257. doi: 10.1186/1745-6215-15-257. Trials. 2014. PMID: 24974155 Free PMC article. Clinical Trial.
-
Is the cosyntropin test redundant in the acutely ill patient suspected of adrenal insufficiency? A case report and literature review.Tenn Med. 2010 Sep;103(8):41-3. Tenn Med. 2010. PMID: 20961018 Review.
-
Corticosteroids in Patients Hospitalized With Community-Acquired Pneumonia: Systematic Review and Individual Patient Data Metaanalysis.Clin Infect Dis. 2018 Jan 18;66(3):346-354. doi: 10.1093/cid/cix801. Clin Infect Dis. 2018. PMID: 29020323
Cited by
-
Effect of nutritional support in patients with lower respiratory tract infection: Secondary analysis of a randomized clinical trial.Clin Nutr. 2021 Apr;40(4):1843-1850. doi: 10.1016/j.clnu.2020.10.009. Epub 2020 Oct 10. Clin Nutr. 2021. PMID: 33081983 Free PMC article. Clinical Trial.
-
From treatment to threat: the fatal impact of cumulative glucocorticoid dosage on outcomes in immunocompromised patients with community-acquired pneumonia.Ther Adv Respir Dis. 2025 Jan-Dec;19:17534666251332085. doi: 10.1177/17534666251332085. Epub 2025 Apr 21. Ther Adv Respir Dis. 2025. PMID: 40257372 Free PMC article.
-
Secondary adrenal insufficiency induced by long-term use of opioid analgesics.Proc (Bayl Univ Med Cent). 2019 May 21;32(3):417-418. doi: 10.1080/08998280.2019.1600180. eCollection 2019 Jul. Proc (Bayl Univ Med Cent). 2019. PMID: 31384206 Free PMC article.
References
REFERENCES
-
- Siemieniuk RA, Alonso-Coello P, Guyatt GH. Corticosteroid therapy for patients hospitalized with community-acquired pneumonia. Ann Intern Med. 2016;164(9):636-637.
-
- Wan YD, Sun TW, Liu ZQ, Zhang SG, Wang LX, Kan QC. Efficacy and safety of corticosteroids for community-acquired pneumonia: a systematic review and meta-analysis. Chest. 2016;149(1):209-219.
-
- Wunderink RG. Corticosteroids for severe community-acquired pneumonia: not for everyone. JAMA. 2015;313(7):673-674.
-
- Christ-Crain M, Stolz D, Jutla S, et al. Free and total cortisol levels as predictors of severity and outcome in community-acquired pneumonia. Am J Respir Crit Care Med. 2007;176(9):913-920.
-
- de Jong MF, Molenaar N, Beishuizen A, Groeneveld AB. Diminished adrenal sensitivity to endogenous and exogenous adrenocorticotropic hormone in critical illness: a prospective cohort study. Crit Care. 2015;19:1.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous